Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.65
HTWR's Cash to Debt is ranked higher than
63% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. HTWR: 1.65 )
HTWR' s 10-Year Cash to Debt Range
Min: 1.03   Max: No Debt
Current: 1.65

Equity to Asset 0.44
HTWR's Equity to Asset is ranked higher than
52% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. HTWR: 0.44 )
HTWR' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.96
Current: 0.44

0.33
0.96
F-Score: 5
Z-Score: 3.10
M-Score: -0.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -22.87
HTWR's Operating margin (%) is ranked higher than
53% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. HTWR: -22.87 )
HTWR' s 10-Year Operating margin (%) Range
Min: -8846.69   Max: -22.87
Current: -22.87

-8846.69
-22.87
Net-margin (%) -28.52
HTWR's Net-margin (%) is ranked higher than
53% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. HTWR: -28.52 )
HTWR' s 10-Year Net-margin (%) Range
Min: -7157.83   Max: -28.52
Current: -28.52

-7157.83
-28.52
ROE (%) -29.86
HTWR's ROE (%) is ranked higher than
54% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. HTWR: -29.86 )
HTWR' s 10-Year ROE (%) Range
Min: -128.6   Max: -17.52
Current: -29.86

-128.6
-17.52
ROA (%) -13.80
HTWR's ROA (%) is ranked higher than
56% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. HTWR: -13.80 )
HTWR' s 10-Year ROA (%) Range
Min: -86.09   Max: -10.99
Current: -13.8

-86.09
-10.99
ROC (Joel Greenblatt) (%) -104.49
HTWR's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 13.69 vs. HTWR: -104.49 )
HTWR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -736.7   Max: -81.47
Current: -104.49

-736.7
-81.47
Revenue Growth (%) 47.00
HTWR's Revenue Growth (%) is ranked higher than
99% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. HTWR: 47.00 )
HTWR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 429.3
Current: 47

0
429.3
EBITDA Growth (%) 6.80
HTWR's EBITDA Growth (%) is ranked higher than
83% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. HTWR: 6.80 )
HTWR' s 10-Year EBITDA Growth (%) Range
Min: -16.8   Max: 35.3
Current: 6.8

-16.8
35.3
EPS Growth (%) 19.40
HTWR's EPS Growth (%) is ranked higher than
87% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. HTWR: 19.40 )
HTWR' s 10-Year EPS Growth (%) Range
Min: -15.5   Max: 42
Current: 19.4

-15.5
42
» HTWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

HTWR Guru Trades in Q3 2013

Steven Cohen 51,699 sh (New)
Manning & Napier Advisors, Inc 280,650 sh (+36.24%)
» More
Q4 2013

HTWR Guru Trades in Q4 2013

Paul Tudor Jones 5,715 sh (New)
Steven Cohen 219,800 sh (+325.15%)
Manning & Napier Advisors, Inc 282,710 sh (+0.73%)
» More
Q1 2014

HTWR Guru Trades in Q1 2014

Jim Simons 27,127 sh (New)
Ron Baron 500,000 sh (New)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Manning & Napier Advisors, Inc 185,526 sh (-34.38%)
» More
Q2 2014

HTWR Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 240,980 sh (+29.89%)
» More
» Details

Insider Trades

Latest Guru Trades with HTWR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 New Buy0.19%$90.83 - $104.66 $ 90.38-7%500000
George Soros 2012-03-31 Sold Out 0.05%$65.86 - $75.83 $ 90.3838%0
George Soros 2011-12-31 Reduce -90%0.15%$58.78 - $70.56 $ 90.3838%15000
George Soros 2011-09-30 Add 900%0.15%$54.9 - $73.88 $ 90.3842%150000
George Soros 2011-06-30 New Buy0.02%$67 - $84.32 $ 90.3822%15000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Heartware International Inc

Baron Funds Comments on HeartWare International - May 05, 2014

We also initiated a position in HeartWare International, Inc. (HTWR), which sells an implantable heart pump for the treatment of advanced heart failure. HeartWare's HVAD is the smallest and lightest pump available and is easier and less invasive to implant. HeartWare is rapidly taking share from its competitor who was first to market.



The NIH estimates up to 100,000 patients just in the U.S., as potential candidates for a left ventrical assist device. The global market is over double that. Only 6,300 devices were implanted globally in 2013, so this market is in a nascent stage of development. Barriers to entry are very high, due to long and arduous clinical and regulatory requirements and we think this will remain a duopoly. HeartWare has a next generation pump in trials that has the potential to be disruptive technology, which could accelerate market adoption and market share gain. They also are developing products that treat earlier stages of heart failure and offer less invasive treatments.



HeartWare did a little over $200 million in revenues last year, and we believe that will more than triple in the next five years. However, the company is not profitable and won't be until 2016. Wall Street values these businesses on revenues, which is something I am uncomfortable with, and we suspect that clinical trials and product rollout will have ups and downs, so we are prepared for a bumpy ride. But if this plays out how we expect, the stock could appreciate over three-fold in the next five years, so it's worth the agita





From Baron Funds' first quarter 2014 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Heartware International Inc

Baron Funds Comments on HeartWare International
We also initiated a position in HeartWare International, Inc. (HTWR), which sells an implantable heart pump for the treatment of advanced heart failure. HeartWare's HVAD is the smallest and lightest pump available and is easier and less invasive to implant. HeartWare is rapidly taking share from its competitor who was first to market. Read more...

Ratios

vs
industry
vs
history
P/B 7.80
HTWR's P/B is ranked higher than
53% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. HTWR: 7.80 )
HTWR' s 10-Year P/B Range
Min: 4.16   Max: 20.13
Current: 7.8

4.16
20.13
P/S 6.60
HTWR's P/S is ranked higher than
57% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. HTWR: 6.60 )
HTWR' s 10-Year P/S Range
Min: 5.83   Max: 130.95
Current: 6.6

5.83
130.95
EV-to-EBIT -24.78
HTWR's EV-to-EBIT is ranked lower than
51% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 44.62 vs. HTWR: -24.78 )
HTWR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -24.78

Current Ratio 5.14
HTWR's Current Ratio is ranked higher than
85% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. HTWR: 5.14 )
HTWR' s 10-Year Current Ratio Range
Min: 1.23   Max: 23.06
Current: 5.14

1.23
23.06
Quick Ratio 4.31
HTWR's Quick Ratio is ranked higher than
86% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. HTWR: 4.31 )
HTWR' s 10-Year Quick Ratio Range
Min: 1.23   Max: 21.57
Current: 4.31

1.23
21.57

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.10
HTWR's Price/Tangible Book is ranked higher than
56% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 6.18 vs. HTWR: 20.10 )
HTWR' s 10-Year Price/Tangible Book Range
Min: 4.82   Max: 20.89
Current: 20.1

4.82
20.89
Price/Median PS Value 0.50
HTWR's Price/Median PS Value is ranked higher than
97% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. HTWR: 0.50 )
HTWR' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 9.51
Current: 0.5

0.49
9.51
Forward Rate of Return (Yacktman) 11.73
HTWR's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. HTWR: 11.73 )
HTWR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 15.7   Max: 30.2
Current: 11.73

15.7
30.2

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:HIN.Australia, X1H.Germany, HIY1.Germany
Heartware International, Inc., was incorporated in Delaware on July 29, 2008 and became the successor issuer to HeartWare Limited, an Australian corporation, on November 13, 2008, as a result of the Australian Court approved redomiciliation of HeartWare Limited from Australia to Delaware. HeartWare is a medical device company engaged in developing implantable blood pumps for the treatment of advanced heart failure. The Company operates one reportable segment which includes the design, manufacture and marketing of medical devices for the treatment of advanced heart failure. The HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients with advanced heart failure. Beyond the HeartWare System, the company is also evaluating its next device, the Miniaturized Ventricular Assist Device. The MVAD is based on the same technology platform as the HeartWare System but adopts an axial flow, rather than a centrifugal flow, configuration and is being developed in multiple configurations. The MVAD designs are currently at the preclinical stage and undergoing animal studies focused on minimally invasive implantation techniques and are each approximately one-third the size of the HVAD Pump. HEARTWARE, HVAD and MVAD, KRITON and various company logos are the trademarks of the Company, in the United States, Australia and other countries.
» More Articles for HTWR

Headlines

Articles On GuruFocus.com
Baron Funds Comments on HeartWare International May 05 2014 
Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 2,857 Shares Feb 24 2011 
Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 21,834 Shares Apr 30 2010 
Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 5,271 Shares Mar 09 2010 
Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 3,300 Shares Feb 26 2010 
Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 4,967 Shares Jan 29 2010 
Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 2,521 Shares Dec 07 2009 
Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 1,580 Shares Dec 03 2009 
Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 3,400 Shares Nov 30 2009 
Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 3,415 Shares Nov 24 2009 


Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide